News
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in
By: benzinga
- Oct 22 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS
Share this page
Guest Posts by Easy Branches
